Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a Phase 2 Clinical Trial of the TLR 7/8 dual ...
EDISON, N.J.--(BUSINESS WIRE)--Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announced today that the first …